Mozart Therapeutics develops CD8 Treg modulators to create disease-modifying therapies for autoimmune and inflammatory diseases. Its lead candidate, MTX-101, is a bispecific autoimmune checkpoint inhibitor planned for IND submission and a Phase 1 first-in-human trial in early 2024. An additional cytokine-based CD8 Treg network modulator is in preclinical development. The company is led by President and CEO Katie Fanning. Mozart intends to use the new funding to advance MTX-101 into human trials and to support pipeline expansion. Financially, the company expanded its Series A with a $25M extension, bringing total capital raised to $80M. Mozart Therapeutics is a Seattle biotech developing compounds that boost regulatory CD8 T cells to quell overactive immune responses in celiac disease and other autoimmune and inflammatory conditions. Its lead compound aims to increase activity of regulatory CD8 T cells and move through preclinical studies into human testing, with celiac disease trials expected to start in 2024. The company is also building bispecific compounds that bind regulatory CD8 T cells and inhibit the KIR brake, and it has additional compounds targeting different surface receptors. Programs build on research from co-founder Mark Davis’s lab at Stanford, and Mozart believes the approach may apply to type 1 diabetes and inflammatory bowel disease as well. Leadership includes CEO Katie Fanning, CSO Kristine Swiderek, and VP Courtney Crane; the roughly 13-person company plans to expand hires in research and product development. Mozart operates out of lab space near Seattle’s waterfront and raised capital to advance its lead program toward human trials.

Total raised

$80M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2023